Despite ongoing advancements in genomics, artificial intelligence, and precision medicine, clinical trial success rates have remained low, with approximately 90-95% of drug candidates failing during ...

Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth ...

Bristol Myers Squibb has said it is the first life sciences company to buy a new AI supercomputing infrastructure blueprint ...

In what is thought to be South Korea's largest biopharma acquisition to date, Samsung Biologics has agreed to buy PolyPeptide ...

Three more biotechs have revealed their intentions to list on Nasdaq – BlossomHill, VogenX, and Latigo – as 2026 continues on ...

Venture financing for UK biotechs reached a five-year high in the second quarter of the year, with more than £2 billion ...

New community diagnostic centres, improved screening programmes and investment in technology are helping to catch the disease ...

Illumina has unveiled a database of genomic alterations, called the Billion Cell Atlas, that can be used to identify and validate drug targets and train AI models used in drug discovery. The first ...

Eisai and Biogen have won FDA approval for a subcutaneous injection version of Leqembi that could help accelerate uptake of the Alzheimer's disease therapy. The green light for Leqembi Iqlik ...

Mission Therapeutics of the UK has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, ...

Three years after buying Bellus Health and its chronic cough candidate camlipixant for around $2 billion, GSK is abandoning ...